Related Experiment Video

Updated: Feb 1, 2026

Assessing Specificity of Anticancer Drugs In Vitro
09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

9.8K

Identification of a novel SIRT7 inhibitor as anticancer drug candidate

Ji-Hye Kim1, Dahee Kim2, Suk Joon Cho3

  • 1Division of Innovative Target Research Center, Korea Research Institute of Chemical Technology, Daejeon, 34114, South Korea; Division of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul, 02841, South Korea.

Biochemical and Biophysical Research Communications
|December 4, 2018
PubMed

Insights

Researchers identified a novel SIRT7 inhibitor (ID: 97491) that halts cancer growth. This compound boosts tumor suppressor p53 acetylation, increasing apoptosis and inhibiting cancer progression in vivo.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • Sirtuins (SIRTs) are deacetylases crucial for DNA repair, aging, and metabolism.
  • SIRT7, a nucleolar sirtuin, regulates genomic stability, rDNA transcription, and cell proliferation, impacting tumorigenesis.
  • SIRT7 deacetylates histone H3 and the tumor suppressor p53, suppressing cancer cell growth by reducing p53 activity.

Purpose of the Study:

  • To identify novel inhibitors of SIRT7 deacetylase activity.
  • To evaluate the therapeutic potential of a novel SIRT7 inhibitor (ID: 97491) in cancer treatment.

Main Methods:

  • Dose-dependent inhibition of SIRT7 activity by ID: 97491.
  • Assessment of p53 expression and acetylation levels.
  • Evaluation of apoptotic effects via caspase-related proteins.
  • In vivo studies to assess cancer growth inhibition.

Main Results:

  • ID: 97491 demonstrated dose-dependent inhibition of SIRT7 activity.
  • The inhibitor increased p53 expression and acetylation by inhibiting SIRT7.
  • ID: 97491 promoted apoptosis and suppressed tumor growth in vivo.

Conclusions:

  • ID: 97491 is a potent inhibitor of SIRT7 deacetylase activity.
  • This inhibitor shows potential for preventing tumor progression by stabilizing p53 through acetylation.
  • ID: 97491 represents a promising candidate for cancer therapy.
Keywords:
ApoptosisDeacetylationInhibitorSIRT7p53

More Related Videos

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.6K

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.1K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.3K
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
951